GSK signs gene therapy pact
This article was originally published in Scrip
GlaxoSmithKline reaffirmed its ambitions to build a rare diseases franchise by establishing a strategic alliance with the San Raffaele Telethon Institute for Gene Therapy, a joint venture between Fondazione Telethon and Fondazione San Raffaele, to research and develop gene therapeutic approaches using stem cells derived from patients' bone marrow. In line with the strategy exclusively revealed in Scrip last week (scripintelligence.com, 13 October 2010), GSK has secured an exclusive licence from the Italian institute to develop and commercialise a gene therapy for rare diseases.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.